Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
RAAS inhibitor
Benazepril hydrochloride is a non-peptide angiotensin-converting enzyme (ACE) inhibitor. Reduces blood pressure and myocardial hypertrophy in spontaneous hypertensive rats.
-
ACE inhibitor
Enalapril is an angiotensin converting enzyme (ACE) inhibitor used in the treatment of hypertension and some types of chronic heart failure. -
RAAS inhibitor
Enalaprilat is the active metabolite of enalapril. It is the first dicarboxylate-containing ACE inhibitor and was developed partly to overcome these limitations of captopril. -
HMG-CoA reductase inhibitor
Rosuvastatin is a member of the drug class of statins, used to treat high cholesterol and related conditions, and to prevent cardiovascular disease. -
renin inhibitor
Aliskiren hemifumarate is a hemifumarate salt form of Aliskiren, which is a direct renin inhibitor approved for the treatment of essential hypertension. -
HMG-CoA Reductase inhibitor
Clinofibrate is a lipid clearing agent that appears to modify lipid metabolism, diminishing the steroid induced accumulation of lipids within osteocytes. It also can effectively reduce the plasma fibrinogen level.
-
ACE inhibitor/Beta blocker
Moxonidine is a new-generation centrally-acting antihypertensive drug. It may have a role when thiazides, beta-blockers, ACE inhibitors and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction. -
Renin inhibitor
Aliskiren is an orally active, synthetic nonpeptide renin inhibitor.- Karibe T, .et al. , Drug Metab Dispos, 2018, May;46(5):667-679 PMID: 29358184
-
ACE inhibitor
Cilazapril is a pyridazine angiotensin-converting enzyme inhibitor (ACE inhibitor) used for the treatment of hypertension and congestive heart failure. -
ACE inhibitor
Fosinopril is an angiotensin converting enzyme (ACE) inhibitor used for the treatment of hypertension and some types of chronic heart failure. -
ACE inhibitor
Zofenopril calcium is an angiotensin-converting enzyme ACE inhibitor.- Sona Cacanyiova, .et al. , Biol Res, 2023, Oct 25;56(1):55 PMID: 37875978
- Tomas Jasenovec, .et al. , Biomedicines, 2021, Dec 14;9(12):1902 PMID: 34944718
-
LTA4 hydrolase inhibitor
Captopril Disulfide is a reversible and competitive inhibitor of LTA4 hydrolase (IC50=11 M). Captopril has been shown to be an of angiotensin converting enzyme-1 (ACE1), but not ACE2(IC50 = 22 nM). -
ACE inhibitor
Zofenopril is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 81 μM. -
Renin inhibitor
VTP-27999 HCl is a potent inhibitor of renin with IC50 value of 0.3 nM for human renin. -
angiotensin receptor-neprilysin inhibitor
LCZ696 is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. -
Renin inhibitor
VTP-27999 2,2,2-trifluoroacetate is an alkyl amine Renin inhibitor; VTP-27999 is useful for Hypertension and End-Organ Diseases. -
Enkephalin-degrading and ACE inhibitor
Spinorphin is an endogenous factor that exhibits inhibitory effects on enkephalin-degrading enzymes. -
ACE inhibitor
H-Val-Pro-Pro-OH, a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM. -
ACE inhibitor
Imidaprilate is an active metabolite of TA-6366, acts as a potent angiotensin converting enzyme (ACE) inhibitor, with an IC50 of 2.6 nM, and is used in the research of hypertensive disease. -
angiotensin-converting enzyme inhibitor
Lisinopril (MK-521) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks. -
direct renin inhibitor
Aliskiren D6 Hydrochloride (CGP 60536 D6 Hydrochloride) is is deuterium labeled Aliskiren, which is a direct renin inhibitor with IC50 of 1.5 nM. -
Renin Inhibitor
Aliskiren fumarate is a potent and selective renin inhibitor with an IC50 of 1.5 nM. It is primarily utilized in research related to hypertension and cardiovascular diseases, as well as cancer cachexia. Its mechanism of action involves the inhibition of renin, a key enzyme in the regulation of blood pressure, making it an important tool for studying these conditions. -
Renin Inhibitor
Aliskiren hydrochloride is a potent and selective renin inhibitor, exhibiting an IC50 of 1.5 nM. This compound is widely used in the study of hypertension and cardiovascular diseases, as well as in research related to cancer cachexia. Its ability to modulate renin activity makes it a valuable tool for exploring the pathophysiological mechanisms underlying these conditions. -
Renin/HIV-1 Protease Inhibitor
PD 134922 is a potent inhibitor of renin and HIV-1 protease, exhibiting an IC50 of 15 nM against HIV-1 protease. This compound is valuable in studies focused on the modulation of blood pressure regulation through renin inhibition and provides insights into HIV-1 protease activity. Its application extends to research in antiviral therapies and blood pressure-related disorders, making it a useful tool for scientists in pharmacological studies. -
Renin Inhibitor
CP-69799 is a potent renin inhibitor that functions as a transition-state analogue, specifically targeting hog renin with an IC50 value of 6 nM and human plasma renin with an IC50 of 300 nM. This inhibitor engages the active site of endothiapepsin, inducing domain rotation and impacting thermal dynamics. CP-69799's unique design, featuring a polar lysine residue at the P2' position, allows for effective binding and has implications for hypertension research. Its mechanistic insights make it a valuable reagent for studies focused on modulating renin activity and understanding cardiovascular functions. -
angiotensin-converting enzyme Inhibitor, renin Inhibitor
Lyciumin D functions as both an angiotensin-converting enzyme inhibitor and a renin inhibitor. This compound demonstrates significant potential in the modulation of the renin-angiotensin system, making it a valuable tool for research into hypertension and related cardiovascular conditions. Its multimodal mechanism can facilitate studies aimed at understanding blood pressure regulation and developing therapeutic strategies for hypertension management. -
Renin Inhibitor
Imarikiren hydrochloride is a potent renin inhibitor that disrupts the renin-angiotensin (RA) system. This compound demonstrates significant biological activity in the context of cardiovascular and renal diseases, making it valuable for research related to hypertension, heart failure, and diabetic nephropathy. Its mechanism of action provides insights into the modulation of blood pressure and kidney function, facilitating the exploration of therapeutic strategies for these conditions. -
Renin Inhibitor
SQ 33800 is a highly potent inhibitor of human renin, exhibiting an IC50 value of 0.35 nM. This compound is instrumental in the study of cardiovascular diseases, providing insights into the regulation of blood pressure and fluid balance. Researchers can utilize SQ 33800 to explore the implications of renin inhibition in various cardiovascular-related conditions. -
Direct Renin Inhibitor
SPH3127 is a highly potent and orally active direct renin inhibitor, demonstrating an IC50 of 0.4 nM against recombinant human renin and 0.45 nM for human plasma renin activity. This compound exhibits significant antihypertensive properties, making it a valuable tool for research focused on essential hypertension and related cardiovascular studies. Its mechanism of action as a direct renin inhibitor allows for detailed investigation into the renin-angiotensin-aldosterone system and its implications in hypertension management. -
Renin Inhibitor
Zankiren is a selective renin inhibitor that reduces the formation of angiotensin II, leading to its renal vasodilator effects. This compound is valuable for research focused on hypertension and cardiovascular diseases, as it specifically modulates renal hemodynamics without interfering with other vasodilatory pathways. Its ability to target renin makes Zankiren an important tool for studying the renin-angiotensin system and its implications in various pathological conditions. -
Renin Inhibitor
SQ 32970 is a tripeptidic inhibitor targeting renin, a key enzyme in the regulation of blood pressure. This compound exhibits potent inhibition of endothia protease activity, making it valuable for studies related to hypertension and cardiovascular research. SQ 32970 serves as a useful tool for investigating the physiological and pathological roles of the renin-angiotensin system. -
Renin Inhibitor
SQ 31844 is a novel renin inhibitor from the imidazolidinol class, specifically targeting the enzyme renin. This compound demonstrates potent in vitro inhibition of primate renin while showing no significant effects on renin from rat, pig, or dog. In vivo studies in sodium-deprived cynomolgus monkeys reveal a dose-dependent reduction in plasma renin activity (PRA) and arterial blood pressure, particularly at higher intravenous doses. Notably, oral administration of SQ 31844 at 50 μmol/kg leads to an 80% reduction in PRA. SQ 31844 serves as a valuable tool for exploring renin-related cardiovascular research and hypertension studies. -
Renin Inhibitor
Renin IN-2 is a selective inhibitor of human renin, exhibiting an IC50 value of 0.059 μM. This compound demonstrates oral efficacy and is applicable in the study of hypertension. Research utilizing Renin IN-2 can provide insights into renin's role in the regulation of blood pressure and related cardiovascular conditions. -
Renin Inhibitor
Renin-IN-4 is a potent renin inhibitor that modulates the renin-angiotensin system. This compound is primarily studied for its implications in cardiovascular diseases, as it plays a crucial role in regulating blood pressure and fluid balance. Renin-IN-4 serves as a valuable tool for investigating the pathophysiology of hypertension and related cardiovascular disorders. -
Renin Inhibitor
Ciprokiren is a potent renin inhibitor, exhibiting IC50 values of 0.07 nM in buffer and 0.65 nM in plasma. This compound can be applied transdermally while maintaining hemodynamic effects without reducing plasma renin activity or plasma immunoreactive angiotensin II levels. Ciprokiren demonstrates significant antihypertensive efficacy, making it a valuable tool for hypertension research and the study of renin-angiotensin system modulation. -
Renin Inhibitor
CGP 29287 is a potent inhibitor of renin, the enzyme responsible for the conversion of angiotensinogen to angiotensin I in the renin-angiotensin system. By selectively inhibiting renin activity, CGP 29287 plays a critical role in studying the regulation of blood pressure and cardiovascular function. This compound is useful in research applications focusing on hypertension, heart failure, and related metabolic disorders. -
Renin Inhibitor
CP-85339 is a tetrapeptide compound that functions as a selective renin inhibitor, effectively modulating the renin-angiotensin-aldosterone system. It demonstrates significant biological activity by decreasing plasma renin levels, which can contribute to lowering blood pressure. This reagent is utilized in research applications related to cardiovascular diseases and hypertension studies, providing insights into the therapeutic potential of renin inhibition. -
Renin Inhibitor
SQ 30774 is a selective renin inhibitor that demonstrates potent in vitro activity in primate models. This compound effectively reduces plasma renin activity (PRA) and has been shown to lower arterial blood pressure in vivo. SQ 30774 is valuable for research applications focusing on hypertension and the renin-angiotensin system, providing insights into cardiovascular regulation and potential therapeutic interventions. -
Renin Inhibitor
Terlakiren is an orally active renin inhibitor that effectively modulates blood pressure regulation. With an IC50 value of 0.7 nM against human renin, Terlakiren demonstrates potent inhibition, making it a valuable tool for studying hypertension and related cardiovascular conditions. This compound is useful in research focused on renin-angiotensin system modulation and potential therapeutic interventions for hypertension. -
Renin Inhibitor
L-363564 is a potent renin inhibitor that plays a critical role in the modulation of the renin-angiotensin-aldosterone system (RAAS). This compound is primarily utilized in cardiovascular disease research, aiding in the investigation of hypertension and related conditions. Its ability to effectively inhibit renin activity makes it a valuable tool for exploring therapeutic strategies in this area. -
Renin Inhibitor
CGP 44099 is a selective renin inhibitor that plays a critical role in the modulation of the renin-angiotensin system. This compound is particularly valuable for research on ischemic injury and the mechanisms underlying reperfusion arrhythmias in rat heart models, providing insights into cardiovascular pathophysiology and potential therapeutic interventions. -
Renin inhibitor
SR 42128 is a potent renin inhibitor that primarily targets the renin-angiotensin system. This compound demonstrates significant inhibition of primate renin activity, while exhibiting reduced efficacy against renins from other species. SR 42128 is valuable for research applications focused on hypertension, cardiovascular disease, and renal function studies. -
Renin Inhibitor
Ditekiren is a pseudohexapeptide renin inhibitor that targets the renin-angiotensin system. It effectively inhibits renin activity, leading to a reduction in the formation of angiotensin II, a key vasoconstrictor involved in blood pressure regulation. This compound is valuable for research applications focused on hypertension, cardiovascular physiology, and fluid balance studies. -
Renin Inhibitor
U-80125 is a competitive inhibitor of human renin, demonstrating an IC50 value of 2.3 μM. This dansylated peptide is characterized by excitation and emission maxima at 340 and 530 nm, respectively. U-80125 is valuable for research focused on hypertension and cardiovascular disease, facilitating the study of renin's role in the renin-angiotensin-aldosterone system. -
Renin Inhibitor
MK-8141 (ACT-077825) is a selective renin inhibitor that increases immunoreactive renin (ir-AR) levels by up to sevenfold. Its primary research applications are focused on evaluating antihypertensive efficacy in hypertensive models. Although MK-8141 demonstrates changes in ir-AR, it does not result in sustained reductions in plasma renin activity (PRA) and does not produce significant blood pressure-lowering effects. -
Renin Inhibitor
Renin-IN-3 is a potent renin inhibitor that selectively targets the renin-angiotensin system. It has demonstrated significant biological activity in modulating blood pressure, making it a valuable tool for hypertension research. This compound can be utilized to explore mechanisms of renal function and cardiovascular regulation in various experimental models.
